Another new drug has been approved by the FDA: romiplostim (Nplate)
This is an agent designed to help patients who have a condition called chronic immune thrombocytopenic purpura (ITP), a blood disorder that can cause serious bleeding. Romiplostim is a novel peptide antibody that stimulates platelet production by mimicking the action of thrombopoietin. GlaxoSmithKline and MGI Pharma both have agents in development that may increase platelets in patients with ITP.
No comments:
Post a Comment